Risks and limits of Abnehmspritze Ernährung

The question about risks and limits of weight loss injections (GLP-1 agonists like semaglutide) in the context of nutrition is valid, but the provided knowledge contexts contain no specific studies or guidelines on these drugs. Therefore, the answer must be conservative and evidence-aware. GLP-1 agonists are prescription medications indicated for obesity or type 2 diabetes—not for cosmetic weight loss. Risks include gastrointestinal side effects (nausea, vomiting, diarrhea), gallstones, pancreatitis, and potential muscle loss with rapid weight loss. Nutritionally, there is a risk of malnutrition (especially protein and vitamins) and inadequate caloric intake. A rebound effect after discontinuation is common. Limits include lack of long-term safety data (cardiovascular endpoints only proven for semaglutide in diabetics) and insufficient evidence for individual genetic or metabolic predispositions. MyBody-X tests (DNA, biomarkers) cannot provide personalized predictions of efficacy or risks for such injections. The evidence level is best classified as 'marketing' or 'unclear' because the contexts contain no validated data. Important: Any use should be medically supervised, and nutrition must be adapted to prevent deficiencies.